Alector, Inc.

Equities

ALEC

US0144421072

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 09/05/2024 am IST			5-day change	1st Jan Change
5.19 ^USD	-2.08%		-1.70%	-34.96%

08/05	Alector, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
17/04	Certain Restricted Stock Units of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	CI

Alector, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

February 28, 2024 at 02:40 am IST

Alector, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 41.43 million compared to USD 52.43 million a year ago. Basic loss per share from continuing operations was USD 0.49 compared to USD 0.63 a year ago.

Latest news about Alector, Inc.

Alector, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Certain Restricted Stock Units of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	17/04	CI
Certain Options of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	17/04	CI
Certain Common Stock of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	17/04	CI
Alector, Inc. Announces Board Changes	22/03	CI
Transcript : Alector, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM	13/03
Transcript : Alector, Inc., 2023 Earnings Call, Feb 27, 2024	28/02
Alector, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Alector, Inc. Provides Revenue Guidance for the Year Ending 2024	28/02	CI
Alector, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02	CI
Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer?S Disease	08/02	CI
Alector, GSK Say FDA Grants Breakthrough Therapy Label For Frontotemporal Dementia Treatment	07/02	MT
GSK: breakthrough therapy status in dementia	07/02	CF
Alector, GSK Get FDA Breakthrough Designation for Latozinemab	07/02	DJ
Alector, Inc. Announces the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation to Latozinemab	07/02	CI
Alector Closes $75 Million Public Stock Offering	19/01	MT
Alector Tumbles After Pricing $75 Million Stock Offering	17/01	MT
Sector Update: Health Care Stocks Decline Pre-Bell Wednesday	17/01	MT
Alector Plans Common Stock Offering; Shares Fall After-Hours	17/01	MT
North American Morning Briefing : Volatility -2-	15/12	DJ
Alector Shares Rise After Stifel Upgrade	15/12	MT
Stifel Upgrades Alector to Buy From Hold, Adjusts Price Target to $15 From $8	14/12	MT
Transcript : Alector, Inc. - Special Call	13/12
Deutsche Bank Initiates Coverage on Alector With Buy Rating, $12 Price Target	12/12	MT
Transcript : Alector, Inc. - Special Call	07/12

Chart Alector, Inc.

Duration

Period

More charts

Company Profile

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimerâs disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.

Sector

Biotechnology & Medical Research

Calendar

12/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Alector, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.19 USD

Average target price

16.22 USD

Spread / Average Target

+212.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALECTOR, INC.	-34.96%	500M
VERTEX PHARMACEUTICALS INCORPORATED	+2.93%	108B
ARGENX SE	-0.90%	23.46B
BIONTECH SE	-14.60%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-38.55%	17.45B
BEIGENE, LTD.	-8.83%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+5.51%	13.99B
SAREPTA THERAPEUTICS, INC.	+37.49%	12.53B
VIKING THERAPEUTICS, INC.	+329.39%	8.81B

Bio Therapeutic Drugs